575 related articles for article (PubMed ID: 29907142)
41. Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
Eissa S; Zohny SF; Zekri AR; El-Zayat TM; Maher AM
Med Oncol; 2010 Dec; 27(4):1286-94. PubMed ID: 20012564
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
43. Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
Du L; Duan W; Jiang X; Zhao L; Li J; Wang R; Yan S; Xie Y; Yan K; Wang Q; Wang L; Yang Y; Wang C
J Cell Mol Med; 2018 May; 22(5):2838-2845. PubMed ID: 29516641
[TBL] [Abstract][Full Text] [Related]
44. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of the diagnostic accuracy of UBC
Styrke J; Henriksson H; Ljungberg B; Hasan M; Silfverberg I; Einarsson R; Malmström PU; Sherif A
Scand J Urol; 2017 Aug; 51(4):293-300. PubMed ID: 28422550
[TBL] [Abstract][Full Text] [Related]
46. Analytical and clinical evaluation of a new urinary tumor marker: bladder tumor fibronectin in diagnosis and follow-up of bladder cancer.
Mutlu N; Turkeri L; Emerk K
Clin Chem Lab Med; 2003 Aug; 41(8):1069-74. PubMed ID: 12964816
[TBL] [Abstract][Full Text] [Related]
47. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.
Park HS; Park WS; Bondaruk J; Tanaka N; Katayama H; Lee S; Spiess PE; Steinberg JR; Wang Z; Katz RL; Dinney C; Elias KJ; Lotan Y; Naeem RC; Baggerly K; Sen S; Grossman HB; Czerniak B
J Natl Cancer Inst; 2008 Oct; 100(19):1401-11. PubMed ID: 18812553
[TBL] [Abstract][Full Text] [Related]
48. [Can the combination of bladder ultrasonography and urinary cytodiagnosis replace cystoscopy in the diagnosis and follow-up of tumors of the bladder?].
Cariou G; Maaraoui N; Cortesse A
Prog Urol; 1997 Feb; 7(1):51-5. PubMed ID: 9116739
[TBL] [Abstract][Full Text] [Related]
49. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
[TBL] [Abstract][Full Text] [Related]
50. [NMP-22 in the diagnosis of bladder cancer].
Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juárez F; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; Del Valle Schaan JI; Roca Edreira A; De Diego Rodríguez E; Rado Velázquez MA; Hernández Castrillo A
Actas Urol Esp; 2000 Oct; 24(9):715-20. PubMed ID: 11132442
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
Lee KH
Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
[TBL] [Abstract][Full Text] [Related]
52. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis.
Wild PJ; Fuchs T; Stoehr R; Zimmermann D; Frigerio S; Padberg B; Steiner I; Zwarthoff EC; Burger M; Denzinger S; Hofstaedter F; Kristiansen G; Hermanns T; Seifert HH; Provenzano M; Sulser T; Roth V; Buhmann JM; Moch H; Hartmann A
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1798-806. PubMed ID: 19454613
[TBL] [Abstract][Full Text] [Related]
53. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
de Martino M; Lucca I; Mbeutcha A; Wiener HG; Haitel A; Susani M; Shariat SF; Klatte T
Eur Urol; 2015 Oct; 68(4):552-4. PubMed ID: 26138037
[TBL] [Abstract][Full Text] [Related]
54. Clinical performance and utility of a NNMT-based urine test for bladder cancer.
Pozzi V; Di Ruscio G; Sartini D; Campagna R; Seta R; Fulvi P; Vici A; Milanese G; Brandoni G; Galosi AB; Montironi R; Cecati M; Emanuelli M
Int J Biol Markers; 2018 Jan; 33(1):94-101. PubMed ID: 29148015
[TBL] [Abstract][Full Text] [Related]
55. Voided urine cytology is a useful tool predicting non-muscle-invasive bladder cancer risk before surgery.
Gómez Del Cañizo C; González Ginel I; Martín-Arriscado Arroba C; de la Calle Moreno A; Hernández Arroyo M; Rodríguez Antolín A; Guerrero Ramos F
Urol Oncol; 2024 Aug; 42(8):246.e15-246.e21. PubMed ID: 38664179
[TBL] [Abstract][Full Text] [Related]
56. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
Shariat SF; Casella R; Monoski MA; Sulser T; Gasser TC; Lerner SP
J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389
[TBL] [Abstract][Full Text] [Related]
57. Novel urinary biomarkers for the detection of bladder cancer: A systematic review.
Tan WS; Tan WP; Tan MY; Khetrapal P; Dong L; deWinter P; Feber A; Kelly JD
Cancer Treat Rev; 2018 Sep; 69():39-52. PubMed ID: 29902678
[TBL] [Abstract][Full Text] [Related]
58. Improved Noninvasive Bladder Cancer Diagnosis using Urine Sediments and Novel DNA Methylation Biomarker Panels.
Wang K; Tian Y; Xu H
Clin Lab; 2016; 62(3):327-36. PubMed ID: 27156320
[TBL] [Abstract][Full Text] [Related]
59. Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer.
Erdmann K; Salomo K; Klimova A; Heberling U; Lohse-Fischer A; Fuehrer R; Thomas C; Roeder I; Froehner M; Wirth MP; Fuessel S
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471285
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic and prognostic value of bladder cancer-related transcript markers in urine.
Schmidt J; Propping C; Siow WY; Lohse-Fischer A; Toma M; Baldauf-Twelker A; Hakenberg OW; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Feb; 142(2):401-14. PubMed ID: 26328914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
